% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brabetz:294422,
      author       = {S. Brabetz and S. N. Groebner and N. Jaeger and T. Milde
                      and J. Ecker and F. Selt and O. Witt and J. M. Rusert and J.
                      Koster and S. E. Leary and X.-N. Li and R. J. Wechsler-Reya
                      and J. M. Olson and S. M. Pfister and M. Kool},
      title        = {{PCLN}-05. {A} {BIOBANK} {OF} {PATIENT}-{DERIVED}
                      {MOLECULARLY} {CHARACTERIZED} {ORTHOTOPIC} {PEDIATRIC}
                      {BRAIN} {TUMOR} {MODELS} {FOR} {PRECLINICAL} {RESEARCH}},
      journal      = {Neuro-Oncology},
      volume       = {20},
      number       = {$suppl_2$},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2024-02251},
      pages        = {i155 - i155},
      year         = {2018},
      abstract     = {Identification of multiple distinct subtypes of pediatric
                      brain tumors raises the need for more and better preclinical
                      models reflecting these subtypes. Orthotopic patient-derived
                      xenograft (PDX) models generated by injection of human tumor
                      cells into the brain of NSG mice offer the unique
                      possibility to test novel substances in primary patient
                      tissue in an in vivo environment. Extensive molecular
                      characterization of PDX and matching primary tumor/blood are
                      needed to see how well the PDX represents the original
                      disease, to learn about targetable oncogenic drivers in each
                      model, and to establish or confirm predictive biomarkers. In
                      an ongoing world-wide effort we have generated and fully
                      characterized thus far 130 PDX models reflecting 22 distinct
                      molecular subtypes of pediatric brain tumors. PDX models
                      always retain their molecular subtype as assessed by DNA
                      methylation analysis and in the vast majority of cases also
                      the mutations and copy number alterations when compared to
                      their primary tumors. Most aggressive tumors, such as those
                      having MYC(N) amplifications, are overrepresented in the
                      cohort, but also subtypes which have not been available for
                      preclinical testing before due to lack of genetically
                      engineered mouse models or suitable cell lines are included.
                      All models and corresponding molecular data will become
                      available for the community for preclinical research. Our
                      repertoire of PDX models and corresponding molecular
                      characterizations allow researchers to find the right models
                      for their specific scientific questions. It provides an
                      unprecedented resource to study tumor biology and paves the
                      way for improving treatment strategies for children with
                      malignant brain tumors.},
      ddc          = {610},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1093/neuonc/noy059.574},
      url          = {https://inrepo02.dkfz.de/record/294422},
}